Cargando…

Bone Mineral Density in Antiretroviral Therapy‐Naïve HIV‐1–Infected Young Adult ‐Women Using Depot Medroxyprogesterone Acetate or Nonhormonal Contraceptives in Uganda

Most studies evaluating BMD in human immunodeficiency virus (HIV)‐infected populations have focused on antiretroviral therapy (ART)‐experienced patients. In this study, the association between HIV‐1 and/or depot medroxyprogesterone acetate (DMPA) and BMD among untreated HIV‐1–infected women in a res...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matovu, Flavia Kiweewa, Nabwana, Martin, Kiwanuka, Noah, Scholes, Delia, Isingel, Esther, Nolan, Monica L, Fowler, Mary G, Musoke, Philippa, Pettifor, John M, Brown, Todd T, Beksinska, Mags E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7872338/ https://www.ncbi.nlm.nih.gov/pubmed/33615111 http://dx.doi.org/10.1002/jbm4.10446

Ejemplares similares

Intramuscular depot medroxyprogesterone acetate accentuates bone loss associated with tenofovir disoproxil fumarate-containing antiretroviral therapy initiation in young women living with HIV (the BONE: CARE study): a prospective cohort study in Uganda
por: Kiweewa Matovu, Flavia, et al.
Publicado: (2022)

Bone health and HIV in resource-limited settings: a scoping review
por: Matovu, Flavia Kiweewa, et al.
Publicado: (2016)

The potential for intramuscular depot medroxyprogesterone acetate as a self-bridging emergency contraceptive()
por: Schickler, Robyn, et al.
Publicado: (2020)

High-risk sexual behaviors while on depot medroxyprogesterone acetate as compared to oral contraception
por: Bartz, Deborah, et al.
Publicado: (2017)

Effects of Depot Medroxyprogesterone Acetate, Copper Intrauterine Devices, and Levonorgestrel Implants on Early HIV Disease Progression
por: Morrison, Charles S., et al.
Publicado: (2020)

Weight change among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: Findings from a randomised, multicentre, open-label trial
por: Beksinska, Mags, et al.
Publicado: (2021)

Leukemia Inhibitory Factor: Roles in Embryo Implantation and in Nonhormonal Contraception
por: Salleh, Naguib, et al.
Publicado: (2014)

A platform utilizing Drosophila ovulation for nonhormonal contraceptive screening
por: Jiang, Kewa, et al.
Publicado: (2021)

Incidence of Herpes Simplex Virus Type 2 Infection Among African Women Using Depot Medroxyprogesterone Acetate, a Copper Intrauterine Device, or a Levonorgestrel Implant for Contraception: A Nested Randomized Trial( )
por: Mugo, Nelly R, et al.
Publicado: (2021)

Sexually transmitted infections among women randomised to depot medroxyprogesterone acetate, a copper intrauterine device or a levonorgestrel implant
por: Deese, Jennifer, et al.
Publicado: (2021)

A comparative study on satisfaction from hormonal contraceptives: depot medroxyprogesterone acetate (DMPA), Cyclofem and LD
por: Fathizadeh, Nahid, et al.
Publicado: (2011)

Update to U.S. Selected Practice Recommendations for Contraceptive Use: Self-Administration of Subcutaneous Depot Medroxyprogesterone Acetate
por: Curtis, Kathryn M., et al.
Publicado: (2021)

Nonhormonal drugs and cancer.
por: Stolley, P D, et al.
Publicado: (1995)

Successful treatment of Depot Medroxyprogesterone acetate-related vaginal bleeding improves continuation rates in Adolescents
por: Rager, Kristin M., et al.
Publicado: (2006)

Incidence of Galactorrhea in Young Women Using Depot-Medroxyprogesterone Acetate
por: Omar, Hatim A., et al.
Publicado: (2006)

The effect of depot medroxyprogesterone acetate on tenofovir alafenamide in rhesus macaques
por: Daly, Michele B., et al.
Publicado: (2020)

Ovulation suppression following subcutaneous administration of depot medroxyprogesterone acetate
por: Taylor, Douglas J., et al.
Publicado: (2022)

Depot Medroxyprogesterone Acetate Use and the Development and Progression of Uterine Leiomyoma
por: Harmon, Quaker E., et al.
Publicado: (2022)

Implementation strategies to scale up self-administered depot medroxyprogesterone acetate subcutaneous injectable contraception: a scoping review
por: Aderoba, Adeniyi Kolade, et al.
Publicado: (2023)

Medroxyprogesterone acetate levels among Kenyan women using depot medroxyprogesterone acetate in the FEM-PrEP trial()()
por: Nanda, Kavita, et al.
Publicado: (2016)

A tale of nonhormonal hairs
por: Philip, Rajeev, et al.
Publicado: (2012)

Introducing the subcutaneous depot medroxyprogesterone acetate injectable contraceptive via social marketing: lessons learned from Nigeria's private sector()
por: Liu, Jenny, et al.
Publicado: (2018)

Depo-Provera (depot medroxyprogesterone acetate) use after bariatric surgery
por: Lam, Clarissa, et al.
Publicado: (2016)

Various gene modification techniques to discover molecular targets for nonhormonal male contraceptives: A review
por: Yunaini, Luluk, et al.
Publicado: (2023)

Expanding Access to Injectable Contraception: Results From Pilot Introduction of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC) in 4 African Countries
por: Stout, Anna, et al.
Publicado: (2018)

A randomized crossover study to evaluate local tolerability following subcutaneous administration of a new depot medroxyprogesterone acetate contraceptive formulation()
por: Halpern, Vera, et al.
Publicado: (2023)

An implementation project to expand access to self-administered depot medroxyprogesterone acetate (DMPA)()()
por: Katz, Micah, et al.
Publicado: (2020)

Introduction of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC) Injectable Contraception at Facility and Community Levels: Pilot Results From 4 Districts of Uganda
por: Odwe, George, et al.
Publicado: (2018)

Adolescent and covert family planning users’ experiences self-injecting contraception in Uganda and Malawi: implications for waste disposal of subcutaneous depot medroxyprogesterone acetate
por: Burke, Holly M., et al.
Publicado: (2020)

Dietary intake and eating behavior in depot medroxyprogesterone acetate users: a systematic review
por: Silva, P., et al.
Publicado: (2018)

Depot Medroxyprogesterone Acetate Use and Blood Lead Levels in a Cohort of Young Women
por: Upson, Kristen, et al.
Publicado: (2020)

An updated review on the effects of depot medroxyprogesterone acetate on the mucosal biology of the female genital tract
por: Ayele, Hossaena, et al.
Publicado: (2021)

Multi-omics analysis of the cervical epithelial integrity of women using depot medroxyprogesterone acetate
por: Bradley, Frideborg, et al.
Publicado: (2022)

Optimization of lead compounds into on-demand, nonhormonal contraceptives: leveraging a public–private drug discovery institute collaboration(†)
por: Balbach, Melanie, et al.
Publicado: (2020)

Effects of Depot Medroxyprogesterone Acetate Intramuscular Injection, Copper Intrauterine Device and Levonorgestrel Implant Contraception on Estradiol Levels: An Ancillary Study of the ECHO Randomized Trial
por: Ryan, Rebecca, et al.
Publicado: (2022)

Bone mineral density in midlife long-term users of hormonal contraception in South Africa: relationship with obesity and menopausal status
por: Beksinska, Mags E., et al.
Publicado: (2018)

Counting the costs: Comparing depot medroxyprogesterone acetate and norethisterone oenanthate utilisation patterns in South Africa
por: Smit, Jennifer, et al.
Publicado: (2001)

Vaginal Atrophy following Long-Term Depot Medroxyprogesterone Acetate Use: A Case Report
por: Walker, Christie, et al.
Publicado: (2013)

Effects of depot-medroxyprogesterone acetate on the immune microenvironment of the human cervix and endometrium: implications for HIV susceptibility
por: Smith-McCune, K K, et al.
Publicado: (2017)

Differential effects of depot medroxyprogesterone acetate administration on vaginal microbiome in Hispanic White and Black women
por: Yang, Liying, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_vrvh6g9utdmkqu6933s301qabk